Lexaria Bioscience
LEXX
16 hedge funds and large institutions have $1.68M invested in Lexaria Bioscience in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 3 closing their positions.
275% more capital inflows, than outflows
Capital inflows: $483K | Capital outflows: $129K
2.12% more ownership
Funds ownership: 9.44% → 11.56% (+2.1%)
0% more funds holding
Funds holding: 16 → 16 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invenomic Capital Management
Boston,
Massachusetts
|
+$307K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$114K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$43.5K |
| 4 |
Tower Research Capital (TRC)
New York
|
+$10.3K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.37K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Merit Financial Group
Alpharetta,
Georgia
|
-$63K |
| 2 |
Virtu Financial
New York
|
-$33K |
| 3 |
Two Sigma Investments
New York
|
-$12.4K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$8.59K |
| 5 |
Citigroup
New York
|
-$4K |
LEXX Hedge Fund Activity: Q3 2022 in Review
16 of the 5,833 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2022, worth a combined $1.68M — up 0.6% from $1.67M a quarter earlier.
Fund positioning in LEXX was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 3 added to existing stakes and 5 trimmed.
The largest buyer was Invenomic Capital Management, adding an estimated $307K. The largest seller was Merit Financial Group, exiting entirely with an estimated $63K sold.
- 16 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2022, unchanged from Q2 2022.
- Funds reported $1.68M of Lexaria Bioscience stock for Q3 2022, up 0.6% quarter-over-quarter.
- 3 funds opened new Lexaria Bioscience positions in Q3 2022 and 3 closed out, a net change of 0 holders.
- The largest Lexaria Bioscience buyer in Q3 2022 was Invenomic Capital Management, an estimated $307K added.
- The largest Lexaria Bioscience seller in Q3 2022 was Merit Financial Group, an estimated $63K sold.
Based on aggregated 13F filings for Q3 2022.